Barbara Kosacz

Senior Counsel
Full contact info

Experience

Cell Design Labs Sells to Gilead

December 7, 2017

Cooley advised Cell Design Labs on its sale to Gilead Sciences. The transaction is valued at up to $567 million and includes Gilead’s acquisition of all outstanding shares of Cell Design Labs, including the shares of Cell Design Labs held by Kite Pharma (a subsidiary of Gilead). Partners Ben Beerle and Jamie Leigh led a broad Cooley team advising Cell Design Labs.

Read more

Related contacts

Ben Beerle
Partner, San Francisco
Jamie Leigh
Partner, San Francisco
Danielle Naftulin
Partner, Palo Alto
Rishab Kumar
Partner, Palo Alto
Kate Hillier
Partner, Seattle
Robert L. Jones
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Stephanie Gentile
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Jacqueline Grise
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Joshua Mates
Partner, San Francisco
Barbara Kosacz
Senior Counsel, Palo Alto

Related Practices & Industries

Versartis $145 Million IPO

March 31, 2014

Palo Alto, Calif. – Cooley advised Versartis on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the Nasdaq Global Stock Market under the symbol "VSAR."

Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.

Related contacts

Barbara Kosacz
Senior Counsel, Palo Alto
Kenneth Guernsey
Senior Counsel , San Francisco
Siana Lowrey
Partner, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Michael Tuscan
Partner, Washington, DC
Fraser Brown
Partner, Washington, DC
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Principia Biopharma – $122 Million IPO

October 3, 2018

Cooley advised Principia Biopharma on its $122.2 million initial public offering of 7,187,500 shares of common stock, including the full exercise of the underwriters’ option to purchase additional shares. Lawyers David Peinsipp, Drew Williamson, Barbara Kosacz and Amanda Busch led the Cooley team advising the company.

Bank of America Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as joint book-running managers for the offering. Robert W. Baird acted as lead manager.

Principia Biopharma, which now trades on the Nasdaq Global Select Market as “PRNB,” is a biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

Related contacts

David Peinsipp
Partner, San Francisco
Drew Williamson
Partner, San Francisco
Barbara Kosacz
Senior Counsel, Palo Alto
Melissa H. Boyd
Associate, San Francisco
Anne Lieberman
Partner, Los Angeles Santa Monica

Related Practices & Industries

DBV Technologies Completes Concurrent Public Offerings

November 6, 2014

Cooley advised the underwriters on DBV Technologies' concurrent $106.4 million initial public offering and $28.3 million secondary public offering on Euronext.

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The company trades on the Nasdaq Global Market under the symbol "DBVT" and on Euronext under the symbol "DBV."

Citigroup Global Markets, Leerink Partners and Bryan, Garnier & Co. acted as joint global coordinators and joint book running managers of the global offering.

Related contacts

Marc Recht
Partner, Boston
Div Gupta
Partner, New York
Brian Leaf
Partner, Reston
Barbara Kosacz
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Scott Weston
Partner, Boston
Tamim Bazzi
Partner, New York
Danielle Gershowitz
Partner, New York
Phil Mitchell
Partner, New York
Cynthia Kozakiewicz
Special Counsel, Boston

Related Practices & Industries

Aduro Completes $137 Million IPO

April 30, 2015

Cooley advised Aduro Biotech on its $137 million initial public offering. Aduro is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company trades on the Nasdaq Global Market under the symbol "ADRO." Aduro also raised an additional $25 million in a private placement with Novartis Institutes for BioMedical Research, which closed concurrently with the offering.

Related contacts

Barbara Kosacz
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Bill Christiansen
Partner, Seattle
Lesse Castleberry
Senior Counsel, New York
Jennifer Raab
Partner, Palo Alto
Phil Mitchell
Partner, New York

Related Practices & Industries

View more